332results about How to "Improve compound" patented technology

Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.

This invention features permeability enhancer molecules, and methods, to increase membrane permeability of various molecules, such as nucleic acids, polynucleotides, oligonucleotides, enzymatic nucleic acid molecules, antisense nucleic acid molecules, 2-5A antisense chimeras, triplex forming oligonucleotides, decoy RNAs, dsRNAs, siRNAs, aptamers, or antisense nucleic acids containing nucleic acid cleaving chemical groups, peptides, polypeptides, proteins, carbohydrates, steroids, metals and small molecules, thereby facilitating cellular uptake of such molecules.

The invention relates to bifunctional stapled or stiched peptides comprising a targeting domain, a linker moiety, and an effector domain, that can be used to tether, or to bring into close proximity, at least two cellular entities (e.g., proteins). Certain aspects relate to bifunctional stapled or stiched peptides that bind to an effector biomolecule through the effector domain and bind to a target biomolecule through the targeting domain. Polypeptides and/or polypeptide complexes that are tethered by the bifunctional stapled or stiched peptides of the invention, where the effector polypeptide bound to the effector domain of the bifunctional stapled or stiched peptide modifies or alters the target polypeptide bound to the targeting domain of the bifunctional peptide. Uses of the inventive bifunctional stapled or stiched peptides including methods for treatment of disease (e.g., cancer, inflammatory diseases) are also provided.

An apparatus and method for the phototherapy of different skin conditions, particularly acne vulgaris and seborrhea. The invention transporting compounds, and/or a methylene blue solution. The apparatus includes at least one narrow spectral band light source with spectral emittance concentrated in the violet/blue spectral band and an optical system for controlling spectra and beam parameters of said light source and a mechanical fixture for holding the said light source at an adjustable distance and direction related to the skin treated area, and an electonic unit to control the duration and power and spectral bands of the emitted radiation.

Sulfonate salts have the formula: CF₃—CH(OCOR)—CF₂SO₃⁻M⁺ wherein R is C₁-C₂₀ alkyl or C₆-C₁₄ aryl, and M⁺ is a lithium, sodium, potassium, ammonium or tetramethylammonium ion. Onium salts, oximesulfonates and sulfonyloxyimides and other compounds derived from these sulfonate salts are effective photoacid generators in chemically amplified resist compositions.

A polymeric composition containing at least one polymer and carbon nanotubes is described. The polymeric composition can have carbon nanotubes that are multi-wall carbon nanotubes and/or single-wall carbon nanotubes. The compositions can also contain carbon black. Also described are various articles made from the polymeric compositions including cables and other articles.

The present invention provides for compositions and methods for preparing aqueous insoluble, ductile, flexible silk fibroin films. The silk films comprise silk fibroin and about 10% to about 50% (w/w) glycerol, and are prepared by entirely aqueous processes. The ductile silk film may be further treated by extracting the glycerol from and re-drying the silk film. Active agents may be embedded in or deposited on the glycerol modified silk film for a variety of medical applications. The films may be into 3-dimentional structures, or placed on support surfaces as labels or coatings. The glycerol modified silk films of the present invention are useful in variety of applications such as tissue engineering, medical devices or implants, drug delivery, and edible pharmaceutical or food labels.

A polymer compound comprising a repeating unit represented by the formula (I):

[wherein X¹ and X² are the same or mutually different and represent an oxygen atom, a sulfur atom, —N(R^N)— or C(R^c1)═C(R^c2)—, R¹, R², R³, R⁴, R^N, R^c1 and R^c2 are the same or mutually different and represent a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group, an alkylthio group, an aryl group, an aryloxy group, an arylthio group, an arylalkyl group, an arylalkoxy group, an arylalkylthio group, an arylalkenyl group, an arylalkynyl group, a mono-valent heterocyclic group, a heterocyclic thio group, an amino group, a substituted amino group, a silyl group, a substituted silyl group, an acyl group, an acyloxy group, an imine residue, an amide group, an acid imide group, a carboxyl group, a substituted carboxyl group, a cyano group or a nitro group, and Ar¹ represents a di-valent heterocyclic group.].

N-[1S,2S]-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-trifluoromethyl]pyridine-2-yl}oxy}propanamide (Compound I) has surprisingly improved solubility and bioavailability in a lipophilic vehicle comprising a pharmaceutically acceptable digestible oil, a surfactant, or a cosolvent, or a mixture of any two or more thereof. In one embodiment of the present invention are self-emulsifying or self-microemulsifying composition comprising 1) Compound I; 2) a surfactant having an HLB of 1 to 8; and 3) a surfactant having an HLB of over 8 to 20; and optionally, 4) a digestible oil and/or cosolvent and/or antioxidant or preservative.

Modified natriuretic compounds and conjugates thereof are disclosed in the present invention. In particular, conjugated forms of hBNP are provided that include at least one modifying moiety attached thereto. The modified natriuretic compound conjugates retain activity for stimulating cGMP production, binding to NPR-A receptor, and in some embodiments an improved half-life in circulation as compared to unmodified counterpart natriuretic compounds. Oral, parenteral, enteral, subcutaneous, pulmonary, and intravenous forms of the compounds and conjugates may be prepared as treatments and/or therapies for heart conditions particularly congestive heart failure. Modifying moieties comprising oligomeric structures having a variety of lengths and configurations are also disclosed. Analogs of the natriuretic compound are also disclosed, having an amino acid sequence that is other than the native sequence.

Modified n atriuretic compounds and conjugates thereof are disclosed in the present invention. In particular, conjugated forms of hBNP are provided that include at least one modifying moiety attached thereto. The modified natriuretic compound conjugates retain activity for stimulating cGMP production, binding to NPR-A receptor, and in some embodiments an improved half-life in circulation as compared to unmodified counterpart natriuretic compounds. Oral, parenteral, subcutaneous, and intravenous forms of the compounds and conjugates may be prepared as treatments and/or therapies for heart conditions particularly congestive heart failure. Modifying moieties comprising oligomeric structures having a variety of lengths and configurations are also disclosed. Analogs of the n atriuretic compound are also disclosed, having an amino acid sequence that is other than the native sequence.

The invention discloses method of treatment and reuse of oilfield produced water. The method comprises: providing an aqueous medium comprised at least in part of oilfield produced water; contacting the aqueous medium with a zirconium compound; whereby the fluid viscosity and/or fluid drag reduction ability of the combination of the aqueous medium and zirconium compound is improved compared to the aqueous medium alone; introducing the combination in to the well; and allowing the combination to contact the formation. In another embodiment, the aqueous medium is further contacted by a friction-reduction additive. Still in another embodiment, the aqueous medium is further contacted by a gelling additive. Still in another embodiment, the fluid is energized with a gas.

Disclosed herein are complexes and compounds that pass through cellular barriers to deliver compounds into, through and out of cells, and methods of producing and using such complexes and compounds. The complexes and compounds of the invention comprise a biologically active portion and a targeting element directed to a ligand that confers transcellular, transcytotic or paracellular transporting properties to an agent specifically bound to the ligand. Also disclosed are complexes and compounds that comprise two or more targeting elements directed to a ligand that confers transcellular, transcytotic or paracellular transporting properties to an agent specifically bound to the ligand. Preferred ligands include but are not limited to the stalk of pIgR, a pIgR domain, an amino acid sequence that is conserved among pIgR's from different animals, and one of several regions of pIgR defined herein.

A bowstring cam assembly for compound archery bow has a bowstring cam member that is journaled at an end of the bow power limb. First and second power cams are affixed onto the bowstring cam member to rotate with it, and first and second flexible inextensible cam cables extend over the periphery of the associated power cams. The cam cables and the power cams cooperate to determine draw characteristics for the bow. The bowstring cam member is provided with an acircular cam profile. The second power cam is situated to one side of the axis of the bowstring cam, such that at an end of travel, i.e., at full release, both the first and second power cables are pulling in a common direction.

A photosensitive composition includes a compound represented by Formula (I) and a curable composition contains the compound of Formula (I) and a polymerizable compound. A compound is represented by a Formula (1) and a photocurable composition contains the compound of Formula (1) and a polymerizable compound. In Formula (I), R, R¹ and R² each independently represent a hydrogen atom or a monovalent substituent. In Formula (1), R and B each independently represent a monovalent substituent, A represents a divalent organic group, and Ar represents an aryl group.

Herein is reported a conjugate comprising an antigen and an antibody that specifically binds to the antigen wherein a covalent bond is formed between the antigen and an amino acid residue in the CDR2 of the antibody, an antibody comprising a cysteine residue at amino acid position 53 (according to Kabat) in the heavy chain CDR2 and uses thereof.

A ball grid array device with an insulating substrate (110) having metal traces (106, for example copper, about 18 μm thick) with sidewalls (108) at right angles to the trace top. The traces are grouped in a first (120) and a second set (121). The first set traces have the top surface covered by a thin noble metal (for example a nickel layer (130) about 0.1 μm thick and an outermost gold layer (131) about 0.5 μm thick), while the sidewalls are un-covered by the noble metal. About 1.5 μm are thus gained for the trace spacing; oxidation of the trace sidewalls is enabled. The second set traces have the top surface un-covered by the noble metal; the traces are covered by an insulating soldermask. A semiconductor chip (101) with terminals (102) is attached to the substrate with the terminals connected to the noble metal of the first set traces, either by bonding wires (for example gold) or by metal studs (for example gold). The assembled chip and the first set traces are encapsulated in a polymerized compound (160), which adheres to the oxidized trace sidewalls and locks into the trace undercuts at the substrate interface.

A photocatalytic air treatment system, including an apparatus and method, is provided for killing and/or mineralizing bacteria, viruses, mold, fungi, spores, mycotoxins, allergens, and other similar microorganisms and agents and similar organic matter, and for oxidizing volatile organic compounds. The system comprises one or more reactor beds configured in one or more stages with each reactor bed including a plurality of photocatalyst-coated media substantially surrounding a plurality of sheathed ultraviolet light sources. Adjacent ultraviolet light sources are positioned to create killing zones of photocatalyst coated media that are irradiated with ultraviolet light from the ultraviolet light sources and in which an increased number of hydroxyl radicals are present.

The invention relates to the preparation of a rubber composition containing silica-based filler reinforcement through the utilization of a organosilane disulfide compound mixed with a rubber composition in at least one preparatory, non-productive, mixing stage followed by utilization of an organosilane polysulfide compound mixed with the rubber composition in a subsequent, productive, mixing stage. The invention further relates to the resulting rubber composition and use thereof in tires.

The present invention is directed to conjugates that include a polypeptide capable of crossing the blood-brain barrier or entering one or more cell types attached to a transport vector, i.e., a composition capable of transporting an agent (e.g., a therapeutic agent). In certain cases, the polypeptides are directly conjugated to a lipid or polymeric vector to allow targeted application of a therapeutic agent to treat, for example, a cancer, a neurodegenerative disease, or a lysosomal storage disorder.